Patents by Inventor Thomas E. Eling

Thomas E. Eling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NON-STEROIDAL ANTI-INFLAMMATORY DRUG ACTIVATED GENE WITH ANTI-TUMORIGENIC PROPERTIES
    Publication number: 20090286313
    Abstract: The present invention provides methods and compositions for drug screens to identify and characterize agents that are agonistic or antagonistic to activation of the promoter region of the NAG-1 gene. Activation of the NAG-1 gene is associated with the apoptotic elimination of cancer cells both in vitro and in vivo. The invention also provides novel promoter region sequences of the NAG-1 gene.
    Type: Application
    Filed: May 11, 2009
    Publication date: November 19, 2009
    Applicants: Service
    Inventors: Thomas E. Eling, Seung Joon Baek
  • Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
    Patent number: 7141661
    Abstract: The present invention provides methods and compositions for drug screens to identify and characterize agents that are agonistic or antagonistic to activation of the promoter region of the NAG-1 gene. Activation of the NAG-1 gene is associated with the apoptotic elimination of cancer cells both in vitro and in vivo. The invention also provides novel promoter region sequences of the NAG-1 gene.
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: November 28, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Thomas E. Eling, Seung Joon Baek
  • Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
    Publication number: 20040029770
    Abstract: The present invention provides methods and compositions for drug screens to identify and characterize agents that are agonistic or antagonistic to activation of the promoter region of the NAG-1 gene. Activation of the NAG-1 gene is associated with the apoptotic elimination of cancer cells both in vitro and in vivo. The invention also provides novel promoter region sequences of the NAG-1 gene.
    Type: Application
    Filed: August 15, 2003
    Publication date: February 12, 2004
    Inventors: Thomas E Eling, Seung Joon Baek
  • Synthesis of optically pure thromboxanes
    Patent number: 4256646
    Abstract: In an elegant stepwise process for the production of intermediates of thromboxanes such as TXB.sub.2 from a chiral glucose starting material such as .alpha.-methylglucoside, those steps comprising: ##STR1## A key modification introduced in this synthetic sequence is the use of 4-dimethylaminopyridine for the selective alkylation of primary alcohols in the presence of unprotected secondary alcohols and for the controlled acylation of methylglucoside. The former application has large potential use in the synthesis of nucleosides, polynucleotides, and carbohydrate derivatives.
    Type: Grant
    Filed: April 16, 1979
    Date of Patent: March 17, 1981
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: Oscar Hernandez, John R. Bend, Thomas E. Eling, James D. McKinney